Novartis AG vs Pfizer Inc.: Strategic Comparison

This in-depth comparison examines Novartis AG and Pfizer Inc. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Novartis AG on its own, evaluating Pfizer Inc., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Novartis AG and Pfizer Inc. is widest.

On the headline numbers, annual revenue is $56.7B (FY2025) for Novartis AG and $62.6B (FY2025) for Pfizer Inc., while their respective market capitalizations stand at $275.3B and $160.3B. Novartis AG is headquartered in Switzerland and Pfizer Inc. in United States, and those different home markets shape how each company competes.

Novartis AG: Novartis is one of the world's largest drugmakers by sales and the larger of Basel's two pharmaceutical groups alongside Roche. Created by the 1996 merger of Ciba-Geigy and Sandoz, it shed eye care (Alcon, 2019) and generics (Sandoz, 2023) and now sells only innovative medicines. Its best-known products include Entresto for heart failure, Cosentyx for psoriasis and arthritis, Kisqali for breast cancer, Kesimpta for multiple sclerosis and Pluvicto for prostate cancer. The company is headquartered in Basel, Switzerland.

Pfizer Inc.: Pfizer Inc. (NYSE: PFE) is one of the largest pharmaceutical companies in the world by revenue, headquartered at The Spiral, 66 Hudson Boulevard East, New York. It employs about 75,000 people and sells medicines in more than 180 countries. Its history includes Terramycin, Lipitor (via Warner-Lambert), Viagra, Prevnar (via Wyeth) and the Comirnaty COVID-19 vaccine developed with BioNTech. The company is headquartered in New York City, New York. Pfizer was founded in 1849 in Brooklyn, New York City, by German immigrant cousins Charles Pfizer and Charles F. Erhart as a fine-chemicals business, expanding over 175 years into a global biopharmaceutical giant discovering penicillin, Lipitor, Viagra, and the landmark COVID-19 vaccine Comirnaty.

Novartis AG and Pfizer Inc. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Novartis AG and Pfizer Inc..

Novartis AG business model: Novartis earns almost all of its revenue by selling patented prescription medicines to wholesalers, hospitals, pharmacies and national health systems in about 140 countries. FY2025 net sales of $54.5 billion came from four core areas (cardiovascular-renal-metabolic, immunology, neuroscience and oncology) plus established brands. The model depends on reinvesting roughly a fifth of sales into R&D and acquisitions so that new launches replace drugs losing exclusivity. Since the 2023 Sandoz spin-off, Novartis has no generics business; it also earns smaller "other revenues" (about $2.1 billion in 2025) from royalties and milestones.

Pfizer Inc. business model: Pfizer makes money by selling patented prescription medicines and vaccines to wholesalers, hospitals, governments and pharmacies, with the United States as its largest market. Revenue is concentrated in large franchises such as Eliquis (co-commercialized with Bristol Myers Squibb), the Prevnar pneumococcal vaccines, the Vyndaqel tafamidis family, Ibrance, Xtandi and the Seagen antibody-drug conjugates. Pfizer funds internal R&D but sources much of its pipeline externally through acquisitions (Seagen, Metsera) and licensing deals (Innovent, 3SBio), then uses its regulatory, manufacturing and commercial scale to launch products globally during their exclusivity window.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Novartis AG stack up against those of Pfizer Inc..

Novartis AG competitive advantage: Novartis's edge rests on scale in late-stage development and specialist platforms that are hard to copy. It owns the leading commercial radioligand therapy franchise (Pluvicto and Lutathera) along with dedicated isotope manufacturing sites in the US and Europe, an siRNA cardiovascular drug (Leqvio), and, since February 2026, Avidity Biosciences' antibody-oligonucleotide conjugate platform. Its FY2025 core operating margin of about 40% and free cash flow of $17.6 billion fund buybacks, dividends and bolt-on deals simultaneously.

Pfizer Inc. competitive advantage: Pfizer's advantage is scale in late-stage development, regulatory filings, manufacturing and commercialization. The BioNTech partnership showed it: BioNTech supplied the mRNA science, while Pfizer ran the global Phase 3 trial with more than 40,000 participants, built ultra-cold distribution and manufactured billions of Comirnaty doses. That capability also makes Pfizer a natural buyer or partner for smaller biotechs that lack global reach.

Future prospects matter as much as current results. The growth strategies below explain how Novartis AG and Pfizer Inc. each plan to expand from here.

Novartis AG growth strategy: Novartis concentrates on four therapeutic areas and on the US, its largest market. It pairs internal research with bolt-on acquisitions of late-stage or platform biotechs: Chinook (2023, kidney disease), MorphoSys (2024, myelofibrosis), Kate Therapeutics (2024, gene therapy capsids) and Avidity Biosciences (closed February 27, 2026, about $12 billion, neuromuscular RNA medicines). It is also expanding US manufacturing, including radioligand production capacity.

Pfizer Inc. growth strategy: Pfizer's growth plan has three parts. Oncology: the $43 billion Seagen deal (closed December 2023) added Padcev, Adcetris, Tukysa and Tivdak, and Pfizer licensed 3SBio's PD-1xVEGF bispecific in 2025 and signed a 12-program cancer collaboration with Innovent Biologics in May 2026 ($650 million upfront, up to $10.5 billion total). Obesity: Pfizer acquired Metsera in November 2025 for about $10 billion including contingent value rights, after a bidding contest with Novo Nordisk. Cost: a multi-year cost realignment and manufacturing optimization program funds R&D and protects margins.

A closer look at the financial trajectory of Novartis AG and Pfizer Inc. rounds out the comparison.

Novartis AG: Novartis grew FY2025 net sales 8% to $54.5 billion with a core operating margin above 40% and free cash flow of $17.6 billion. 2026 is a reset year: US generics of Entresto and Promacta cut Q1 2026 net sales 5% at constant currencies to $13.1 billion and core operating income 14%. Q2 2026 net sales rose 1% cc to $14.4 billion with a 41.2% core margin, though net income fell 19%. Management guides for low single-digit sales growth and a low single-digit decline in core operating income for 2026 at constant currencies. Novartis is a Swiss multinational pharmaceutical corporation with a market valuation generally exceeding $200 billion.

Pfizer Inc.: Pfizer revenue rose from $41.7 billion in 2020 to $81.3 billion in 2021 and $101.2 billion in 2022 on Comirnaty and Paxlovid, then fell to $59.6 billion in 2023 as COVID demand collapsed. It recovered to $63.6 billion in 2024 and was $62.6 billion in 2025, with net income of $7.8 billion. In Q2 2026 revenue was $15.0 billion, up 1% operationally, or 5% excluding COVID products, and Pfizer raised the midpoint of its 2026 revenue guidance to $60.5 billion to $62.5 billion with adjusted EPS guidance of $2.80 to $3.00. The roughly $31 billion of debt raised for Seagen in 2023 and an ongoing cost-reduction program shape capital allocation alongside a dividend yield near 6%. Pfizer ranks among the largest pharmaceutical companies in the world, carrying a market valuation typically exceeding $150 billion.